Highest-materiality recent filing
CEL-SCI raises $2.5M in common stock offering for Multikine development
2.5M shares sold at $1.00/share, gross proceeds $2.5M; offering closed June 16, 2026.
CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia
50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.
CEL-SCI raises $7.2M in public offering of 6M shares at $1.20/share
Gross proceeds of $7.2 million from 6,000,000 shares at $1.20 per share.
Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.
CEL-SCI closes $5.7M at-the-market offering of 1.5M shares at $3.82
Gross proceeds ~$5.73M before placement agent fees (7%) and up to $95K expenses.
CEL-SCI closes $5M public offering of 2M shares at $2.50/share for Multikine development
Gross proceeds $5M from 2M shares at $2.50; underwriting discount $0.175 per share.
CEL-SCI closes $5M public offering of 16.1M shares at $0.31 for Multikine development
Gross proceeds ~$5M from 7.55M shares + 8.58M pre-funded warrants at $0.31/$0.3099.
CEL-SCI reports Multikine 5-year survival 82.6% in target head & neck cancer subgroup; HR 0.27
Multikine showed 82.6% 5-year overall survival in target low-risk patients vs 47.3% for standard of care.
CEL-SCI closes $10.8M public offering of common stock and pre-funded warrants
Gross proceeds of $10,845,000 from offering of 10,845,000 shares/common stock or pre-funded warrants at $1.00/share.
Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.
CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved
Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.
CEO Geert Kersten's employment extended to August 31, 2027.
Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.
CEL-SCI closes $5M public offering of 2.5M shares at $2.00/share
Closed underwritten public offering of 2,500,000 common shares at $2.00 per share on July 20, 2023.
CEL-SCI prices $5M public offering of 2.5M shares at $2.00/share
Gross proceeds of $5,000,000 from 2.5M shares at $2.00 per share; net proceeds ~$4.5M.
CEL-SCI reports positive FDA meeting for Multikine approval; Canada possible 2024
FDA acknowledged need for improved head/neck cancer treatments; CEL-SCI preparing further development plan.
Low PD-L1 subgroup (TPS<10) showed 20% absolute 5-year overall survival advantage for Multikine+SOC vs SOC alone (60% vs 40% alive).
Offering of 794,117 shares at $1.70 per share; gross proceeds ~$1.35M, net ~$1.12M after discounts and expenses.
CEL-SCI to pursue Health Canada's conditional approval pathway for Multikine in head & neck cancer
Health Canada advised CEL-SCI to request approval under Notice of Compliance with Conditions (NOC/c) policy for Multikine.
CEL-SCI Multikine Phase 3 shows 43% survival extension; BLA submission planned
Multikine extended overall survival by 43% (HR 0.70; 95% CI 0.49-1.00) vs SOC in 352 LR head & neck cancer patients.
Patricia B. Prichep, CEL-SCI’s current senior Vice President of Operations, has assumed the duties of CEL-SCI’s Chief Financial and Operations Officer, effective November 13, 2024.
On April 19, 2024, CEL-SCI Corporation appointed Mario Gobbo to its Board of Directors.
Max materiality 0.85 · Median 0.60 · Most common event other_material